2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting-Reference-Cited by-同舟云学术

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Published:2016-11-04 Issue:1 Volume:25 Page:303-308
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Einhorn Lawrence H.,Rapoport Bernardo,Navari Rudolph M.,Herrstedt Jørn,Brames Mary J.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-016-3449-y.pdf

Reference30 articles.

1. Einhorn LH, Grunberg SM, Rapoport B et al (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 19(Suppl 1):S1–S4

2. Svanberg A, Birgegård G (2015) Addition of aprepitant (Emend®) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology 89:31–36

3. Schmitt T, Goldschmidt H, Neben K et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420

4. Bechtel T, McBride A, Crawford B et al (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911–2916

5. Sakurai M, Mori T, Kato J et al (2014) Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol 99:457–462

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Auriculotherapy and acupuncture treatments for chemotherapy-induced nausea and vomiting: a multicenter clinical trial;Supportive Care in Cancer;2024-07-31

2. Hepatic IRE1α-XBP1 signaling promotes GDF15-mediated anorexia and body weight loss in chemotherapy;Journal of Experimental Medicine;2024-05-02

3. Supportive Therapie;Facharztwissen Hamatologie Onkologie;2024

4. Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis;Supportive Care in Cancer;2023-12-26

5. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting;Supportive Care in Cancer;2023-12-18